Neil Closner – CEO, MedReleaf, Canada
With already 20 percent of market share in the medical cannabis sector in Canada, MedReleaf is getting ready for the upcoming legalization of cannabis for recreational use. The company’s CEO…
Vision‘Diversity of Members, Unity of Voice’
To be the unified Voice of Life Sciences in Ontario by representing the interests of the diverse life sciences community in the province through advocacy, education, facilitation of economic development and promotion of the industry locally, nationally and internationally.
LSO will be the single point of contact for Ontario’s life sciences stakeholders, not only for resolutions to public policy issues, but also to be the conduit between the many organizations in Ontario and our government partners. LSO will work in concert with life science stakeholders to grow the sector in Ontario and to improve our position in the global marketplace. LSO will promote the benefits of life science technologies and work to encourage their commercial success. LSO will continue to operate through the support of its membership and will continue to grow its value proposition to members, stakeholders and governments. LSO will seek to find alignment across our diverse community of life sciences stakeholders and work to complement and support their efforts through partnership and collaboration.
Life Sciences Ontario
109-1 Concorde Gate
Toronto, ON M3C 3N6
phone: 416-426-7293
fax: 416-426-7280
e-mail: admin@lifesciencesontario.ca
http://www.lifesciencesontario.ca/home/index.php
With already 20 percent of market share in the medical cannabis sector in Canada, MedReleaf is getting ready for the upcoming legalization of cannabis for recreational use. The company’s CEO…
Bob McLay, vice president and general manager of Sobi in Canada, discusses how innovation and collaboration with regulators and payers are helping Sobi to bring its medicines to Canadians suffering…
Referring to the Canadian affiliate of Zimmer Biomet as a “trailblazer”, Dave O’Neil looks back on a successful 2017 for the musculoskeletal healthcare company in Canada. He describes how Zimmer…
Looking back on 40 years of commitment to Canada, Servier also celebrates 20 years of R&D activity in the country. On this two-fold anniversary, Frédéric Fasano highlights some of the…
Dwight Gorham, president and CEO of Pillar5 Pharma, discusses the unique positioning of the CDMO in the multi-dose preservative free sterile ophthalmics space and stresses the importance of anticipating market…
Despite its relative youth, Canada’s medical cannabis industry is already presenting some of the characteristics of the much more mature pharmaceutical industry. There is consolidation as well as the first…
Susanne Picard, founder and president at SPharm, speaks about how her passion for regulatory affairs led her to found her own consultancy in 1997 and how the company can look…
Having managed the Canadian affiliate of Otsuka from its infancy steps, Allison Rosenthal, general manager, highlights the affiliate’s feat to exceed expectations for the performance of each of its launches…
Having just announced the first collaboration between a medical cannabis company and a major pharmaceutical player, Tilray expects to launch its first co-branded product with Sandoz Canada by the end…
Looking back on three years of operations in Canada and nine months of approval of Ocaliva® for the rare non-viral liver disease PBC, Brian Canestraro, general manager of Intercept, is…
Lee Ferreira, newly-appointed general manager of Ferring Pharmaceuticals Canada, shares her excitement about the company’s transformative changes. She stresses the importance of conducting research in Canada in all areas of…
After 35 years in the pharmaceutical industry, Barry Fishman shares his excitement about heading one of Canada’s leading licensed cannabis producers. He explains how his experience in the world of…
See our Cookie Privacy Policy Here
